NLG919 27337-2 from BPS Bioscience, Inc.

Description

NLG919 is an orally available potent inhibitor of the indoleamine-2,3- dioxygenase (IDO) pathway, a crucial pathway involved in allergic inflammation that mediates immunosuppressive effects through metabolization of tryptophan to kynurenine. NLG919 affects differentiation and proliferation of T cells by inducing downstream signaling via GCN2, mTOR and AHR, with values of Ki = 7 nM and EC50 = 75 nM. NLG919 is being investigated for the treatment of immunosuppression associated with cancer

Product Specs
ItemNLG919
CompanyBPS Bioscience, Inc.
Price $590.00Supplier Page View Company Product Page
Catalog Number27337-2
Size50 mg
ActivityNLG919 potently blocks IDO-induced T cell suppression and restored T cell responses with a reported ED50 of 80 nM in vitro. NLG919 reduced the concentration of plasma and tissue kynurenine by ~50% after a single dose in mice. NLG919 enhanced the antitumor responses of naÍve, resting pmel-1 T-cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA in mice bearing B16F10 tumors
Purity≥98%
Molecular Weight282.4 Da
FormulaC₁₈H₂₂N₂O
TypeInhibitor
FormatWhite powder